Bank of New York Mellon’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $50.8M | Buy |
4,506,400
+506,219
| +13% | +$5.71M | 0.01% | 987 |
|
|
2025
Q1 | $40.4M | Buy |
4,000,181
+560,641
| +16% | +$5.66M | 0.01% | 1090 |
|
|
2024
Q4 | $40.7M | Buy |
3,439,540
+510,398
| +17% | +$6.04M | 0.01% | 1146 |
|
|
2024
Q3 | $33.8M | Buy |
2,929,142
+242,604
| +9% | +$2.8M | 0.01% | 1270 |
|
|
2024
Q2 | $28.4M | Buy |
2,686,538
+58,541
| +2% | +$619K | 0.01% | 1375 |
|
|
2024
Q1 | $27.7M | Buy |
2,627,997
+1,309,483
| +99% | +$13.8M | 0.01% | 1392 |
|
|
2023
Q4 | $14.8M | Buy |
1,318,514
+130,586
| +11% | +$1.47M | ﹤0.01% | 1760 |
|
|
2023
Q3 | $13.9M | Buy |
1,187,928
+480,946
| +68% | +$5.62M | ﹤0.01% | 1753 |
|
|
2023
Q2 | $7.13M | Buy |
706,982
+568,197
| +409% | +$5.73M | ﹤0.01% | 2123 |
|
|
2023
Q1 | $1.02M | Buy |
138,785
+5,577
| +4% | +$41.2K | ﹤0.01% | 3119 |
|
|
2022
Q4 | $1.06M | Buy |
133,208
+14,145
| +12% | +$113K | ﹤0.01% | 3162 |
|
|
2022
Q3 | $384K | Buy |
119,063
+4,493
| +4% | +$14.5K | ﹤0.01% | 3716 |
|
|
2022
Q2 | $466K | Buy |
114,570
+67,296
| +142% | +$274K | ﹤0.01% | 3647 |
|
|
2022
Q1 | $233K | Buy |
47,274
+4,335
| +10% | +$21.4K | ﹤0.01% | 4160 |
|
|
2021
Q4 | $433K | Buy |
+42,939
| New | +$433K | ﹤0.01% | 3888 |
|